ARTICLE | Clinical News
Loxo reports updated Phase I data for RET inhibitor
June 2, 2018 1:27 PM UTC
Loxo Oncology Inc. (NASDAQ:LOXO) reported updated response data on Saturday at the American Society of Clinical Oncology meeting in Chicago from the Phase I LIBRETTO-001 trial evaluating its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. LOXO-292 led to a confirmed overall response rate (ORR) of 74%, including 25 partial responses, in 34 evaluable patients with RET fusion-positive cancers.
Loxo shares touched an all-time high in early morning trading before closing off $2.86 to $183.83 on Monday...
BCIQ Target Profiles